General Information of Drug Transporter (DT)
DT ID	DTD0056 Transporter Info
Gene Name	ABCC10
Protein Name	Multidrug resistance-associated protein 7
Gene ID	89845
UniProt ID	Q5T3U5
Genetic Polymorphisms of DT (GPD)
Genetic Polymorphism	rs2125739
Site of GPD	chr6:43445127 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	C=0.2001/1002 (Global)
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Nevirapine	Drug Info	HIV Infection	Correlated with the increased likelihood of lower nevirapine plasma concentrations in patients (compare with Genotypes CT + TT)		[ 1]
Nevirapine	N.A.	Nephrotoxicity	Genotype CC is associated with increased likelihood of lower nevirapine plasma concentrations when treated with nevirapine in people with HIV Infections as compared to genotypes CT + TT.		[ 1]
Nevirapine	N.A.	HIV Infectious Disease	Genotype CC is associated with increased likelihood of lower nevirapine plasma concentrations when treated with nevirapine in people with HIV Infections as compared to genotypes CT + TT.		[ 1]
Allele C	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Tenofovir	N.A.	Leukopenia	Allele C is associated with increased kidney tubular dysfunction when treated with tenofovir in people with HIV Infections as compared to allele T.		[ 2]
Nevirapine	N.A.	Toxic Liver Disease	Allele C is not associated with increased risk of Toxic liver disease when treated with nevirapine in people with HIV Infections as compared to allele T.		[ 3]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Docetaxel	N.A.	Nephrotoxicity	Genotype TT is associated with increased sensitivity to docetaxel in 18 NSCLC cell lines as compared to genotypes CC + CT.		[ 4]
Nevirapine	N.A.	HIV Infectious Disease	Patients with the TT genotype and HIV may have increased concentrations of nevirapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence concentrations of nevirapine.		[ 1]
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Nevirapine	N.A.	Nephrotoxicity	Allele T is not associated with increased risk of Stevens-Johnson Syndrome/Epidermal Necrolysis, Toxic when treated with nevirapine in people with HIV Infections as compared to allele C.		[ 5]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Docetaxel	N.A.	Neutropenia	Genotype CT is associated with decreased severity of Neutropenia when treated with docetaxel in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.		[ 4]
Nevirapine	N.A.	HIV Infectious Disease	Patients with the CT genotype and HIV may have increased concentrations of nevirapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence concentrations of nevirapine.		[ 1]
Genetic Polymorphism	rs9349256
Site of GPD	chr6:43436773 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	A=0.3646/1826 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Tenofovir	Drug Info	HIV Infection	Correlated with the increased kidney tubular dysfunction in patients (compare with Allele A)		[ 2]
Tenofovir	N.A.	Leukopenia	Allele G is associated with increased kidney tubular dysfunction when exposed to tenofovir as compared to allele A.		[ 2]
Genotypes AG + GG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Tenofovir Disoproxil Fumarate	N.A.	Nephrotoxicity	Genotypes AG + GG are associated with increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate in people with HIV Infections as compared to genotype AA.		[ 6]
Tenofovir Disoproxil Fumarate	N.A.	HIV Infectious Disease	Genotypes AG + GG are associated with increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate in people with HIV Infections as compared to genotype AA.		[ 6]
Allele A	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Tenofovir Disoproxil Fumarate	N.A.	Nephrotoxicity	Allele A is not associated with severity of nephrotoxicity due to tenofovir disoproxil fumarate in people with HIV Infections as compared to allele G.		[ 7]
Tenofovir Disoproxil Fumarate	N.A.	HIV Infectious Disease	Allele A is not associated with severity of nephrotoxicity due to tenofovir disoproxil fumarate in people with HIV Infections as compared to allele G.		[ 7]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Tenofovir	N.A.	Nephrotoxicity	Patients with the AA genotype may have decreased but not absent risk for kidney tubular dysfunction when exposed to tenofovir as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's risk for adverse events.		[ 2]
Tenofovir Disoproxil Fumarate	N.A.	HIV Infectious Disease	Patients with HIV and the rs9349256 AA genotype may experience a decreased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence severity of nephrotoxicity when treated with tenofovir disoproxil fumarate.		[ 7]
Tenofovir Disoproxil Fumarate	N.A.	Nephrotoxicity	Patients with HIV and the rs9349256 AA genotype may experience a decreased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence severity of nephrotoxicity when treated with tenofovir disoproxil fumarate.		[ 7]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Tenofovir	N.A.	Nephrotoxicity	Patients with the AG genotype may have increased risk for kidney tubular dysfunction when exposed to tenofovir as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.		[ 2]
Tenofovir Disoproxil Fumarate	N.A.	HIV Infectious Disease	Patients with HIV and the rs9349256 AG genotype may experience an increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence severity of nephrotoxicity when treated with tenofovir disoproxil fumarate.		[ 7]
Tenofovir Disoproxil Fumarate	N.A.	Nephrotoxicity	Patients with HIV and the rs9349256 AG genotype may experience an increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence severity of nephrotoxicity when treated with tenofovir disoproxil fumarate.		[ 7]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Tenofovir	N.A.	Nephrotoxicity	Patients with the GG genotype may have increased risk for kidney tubular dysfunction when exposed to tenofovir as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.		[ 2]
Tenofovir Disoproxil Fumarate	N.A.	HIV Infectious Disease	Patients with HIV and the rs9349256 GG genotype may experience an increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence severity of nephrotoxicity when treated with tenofovir disoproxil fumarate.		[ 7]
Tenofovir Disoproxil Fumarate	N.A.	Nephrotoxicity	Patients with HIV and the rs9349256 GG genotype may experience an increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence severity of nephrotoxicity when treated with tenofovir disoproxil fumarate.		[ 7]
Genetic Polymorphism	rs1214763
Site of GPD	chr6:43392523 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A / T>C / T>G
Minor Allele Frequency	T=0.0970/191 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Daunorubicin	N.A.	Cardiotoxicity	Allele T is associated with decreased likelihood of cardiotoxicity when treated with daunorubicin or doxorubicin in children with Neoplasms as compared to allele C.		[ 8]
Doxorubicin	N.A.	Cardiotoxicity	Allele T is associated with decreased likelihood of cardiotoxicity when treated with daunorubicin or doxorubicin in children with Neoplasms as compared to allele C.		[ 8]
Genetic Polymorphism	rs4714684
Site of GPD	chr6:43429118 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>C / A>T
Minor Allele Frequency	A=0.5990/1185 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Drugs For Treatment Of Tuberculosis	N.A.	Toxic Liver Disease	Allele A is not associated with risk of Toxic liver disease due to Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to allele C.		[ 9]
Genetic Polymorphism	rs2185631
Site of GPD	chr6:43440267 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G / A>T
Minor Allele Frequency	A=0.6120/1211 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Drugs For Treatment Of Tuberculosis	N.A.	Toxic Liver Disease	Allele A is not associated with risk of Toxic liver disease due to Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to allele G.		[ 9]
References
1	Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. Pharmacogenet Genomics. 2012 Jan;22(1):10-9.
2	Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction. J Infect Dis. 2011 Jul 1;204(1):145-53.
3	ABCC10 rs2125739 polymorphism and nevirapine-induced hepatotoxicity: lack of association in a population from Mozambique. Pharmacogenet Genomics. 2013 Jan;23(1):38-9.
4	Genetic variation in the ATP binding cassette transporter ABCC10 is associated with neutropenia for docetaxel in Japanese lung cancer patients cohort. BMC Cancer. 2019 Mar 19;19(1):246.
5	Association between CYP2B6 polymorphisms and Nevirapine-induced SJS/TEN: a pharmacogenetics study. Eur J Clin Pharmacol. 2013 Nov;69(11):1909-16.
6	ABCC4 single-nucleotide polymorphisms as markers of tenofovir disoproxil fumarate-induced kidney impairment. Pharmacogenomics J. 2021 Oct;21(5):586-593.
7	Pharmacogenetic determinants of kidney-associated urinary and serum abnormalities in antiretroviral-treated HIV-positive patients. Pharmacogenomics J. 2020 Apr;20(2):202-212.
8	Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children. Pharmacogenomics. 2015;16(10):1065-76.
9	Association of ABCC Gene Polymorphism With Susceptibility to Antituberculosis Drug-Induced Hepatotoxicity in Western Han Patients With Tuberculosis. J Clin Pharmacol. 2020 Mar;60(3):361-368.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.